摘要
目的观察慢性乙型肝炎患者恩替卡韦治疗前后血清中乙型肝炎病毒(HBV DNA)载量与TGF-β1变化,分析其疗效,为临床合理应用恩替卡韦治疗慢性乙型肝炎提供参考。方法选取63例慢性乙型肝炎患者,将其按随机原则分为恩替卡韦试验组及对照组。试验组33例,其中轻度9例、中度17例、重度7例,分别口服恩替卡韦0.5 mg,1次/d,同时加用一般护肝药;对照组30例,其中轻度13例、中度12例、重度5例,单用一般护肝药。分别于治疗前、治疗3个月、治疗6个月,检测血清中HBV DNA、TGF-β1的含量。采用SPSS13.0系统软件进行统计分析。结果恩替卡韦试验组轻度、中度和重度患者血清中HBV DNA载量治疗后呈下降趋势,治疗3个月、6个月与治疗前比较有统计学差异(P<0.05)。试验组中度和重度患者血清TGF-β1水平治疗后呈下降趋势,重度患者治疗6个月与治疗前比较有统计学差异(P<0.05)。结论恩替卡韦试验组慢性乙型肝炎(轻度、中度、重度)治疗后患者血清中的HBV DNA载量明显下降,同时慢性乙型肝炎(中度、重度)患者血清中的TGF-β1均有下降趋势,其中慢性乙型肝炎重度TGF-β1水平明显下降。
Objective To investigate the changes in serum hepatitis B viral load（HBV DNA） and transformer growth factor-β1（TGF-β1） in patients with chronic hepatitis B after entecavir treatment and evaluates the therapeutic effect of entecavir.Methods Sixty-three patients with chronic hepatitis B were randomly assigned into entecavir group（n=33） and control group（n=30）.The entecavir group consisted of 9 mild,17 moderate,and 7 severe cases,all treated with oral entecavir（0.5 mg daily） and general hepatoprotective drugs;the control group,consisting of 13 mild,12 moderate and 5 severe cases,was treated with the hepatoprotective drugs only.Serum HBV DNA and TGF-β1 were determined before and at 3 and 6 months during the treatment.Results Entecavir treatment reduced serum HBV DNA load in all the cases in entecavir group,and the difference was statistically significant between the levels measured at 3 and 6 months（P0.05）.The treatment also resulted in decreased serum TGF-β1 levels in moderate and severe cases,and the severe cases showed a significant TGF-β1 reduction after a 6-month treatment（P0.05）.Conclusion Entecavir can lower serum HBV DNA load levels in patients with chronic hepatitis B.Entecavir is also effective to reduce serum TGF-β1 levels in moderate and severe cases,especially in the latter.
出处
《南方医科大学学报》
CAS
CSCD
北大核心
2012年第4期589-592,共4页
Journal of Southern Medical University
基金
合肥医学院中青年启动基金(C216)
